According to the Smart Finance APP, YSB (09885) has continuously released announcements on the Hong Kong Stock Exchange, stating that it will repurchase a total of 320,000 shares on January 6, January 7, and January 8, 2025, for a total price of 1.8156 million Hong Kong dollars. The Board of Directors believes that the company's current stock price is below its intrinsic value and does not adequately reflect its business prospects. Actively repurchasing shares not only indicates the company's confidence in its own business development but also demonstrates its commitment to shareholder interests.

Recently, influenza has entered its seasonal epidemic period. Data from the China Center for Disease Control and Prevention shows that the positive rate of influenza viruses continues to rise, with over 99% being H1N1. It is anticipated that multiple respiratory infectious diseases will continue to alternate or overlap this winter and next spring. As the peak season for influenza approaches, the demand for antiviral medications will continue to grow, and related pharmaceutical companies may achieve growth as a result. The sector related to influenza pharmaceuticals is also experiencing an increase.

According to a research report from Industrial Securities, the stability and certainty of growth in the pharmaceutical industry remain unchanged, with the current sector at a historically low level. The cyclical sectors are expected to see a recovery in 2025. If expectations for the economic fundamentals improve, the consumer medical sector (OTC Traditional Chinese Medicine, Medical Services, and chain pharmacies) is likely to rebound, with bullish pharmaceutical investment opportunities anticipated for 2025. A research report from Galaxy Securities indicates that the pharmaceutical sector has undergone a prolonged adjustment, and the overall valuation is at a low level, with public fund holdings underweight. The pharmaceutical market is expected to undergo a recovery, and structural opportunities still exist.

Data from the YSB platform shows that sales of influenza-related and respiratory infectious disease medications have increased significantly recently. In terms of news, with the high incidence of winter influenza, the demand for related medications has surged, driving the strength of the Hong Kong stock market's pharmaceutical sector. As a leading provider of outpatient digital pharmaceutical distribution services, YSB achieved its first profit in the first half of 2024, and its performance is expected to benefit from the catalysis of the influenza season, making future market performance worth looking forward to.